WCN26-4471 CXCL13 Expression in the Lymph Node and Kidney of a Patient with Idiopathic Multicentric Castleman Disease with TAFRO Syndrome

Conclusion:In this real-world study, low-to medium-dose of telitacicept combined with conventional therapy showed good onset efficacy and safety for treating IgA patients.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.